Evidence mapping of clinical research on 35 commonly used oral Chinese patent medicines in treatment of intracerebral hemorrhage.
10.19540/j.cnki.cjcmm.20241009.501
- Author:
Wen ZHANG
1
;
Jun-Jie JIANG
2
;
Yong-Qing MA
1
;
Qiao-Feng LI
1
;
Xing LIAO
2
;
Cheng-Yu WU
1
Author Information
1. School of Chinese Medicine, Nanjing University of Chinese Medicine Nanjing 210023, China.
2. Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences Beijing 100700, China.
- Publication Type:Journal Article
- Keywords:
Chinese patent medicine;
clinical research;
evidence mapping;
intracerebral hemorrhage
- MeSH:
Cerebral Hemorrhage/drug therapy*;
Humans;
Drugs, Chinese Herbal/therapeutic use*;
Medicine, Chinese Traditional;
Nonprescription Drugs/administration & dosage*;
Administration, Oral
- From:
China Journal of Chinese Materia Medica
2025;50(2):555-568
- CountryChina
- Language:Chinese
-
Abstract:
Evidence mapping was used to systematically analyze the clinical research evidence of oral Chinese patent medicines in the treatment of intracerebral hemorrhage(ICH), thus revealing the distribution and quality of evidence in this field. The relevant articles were retrieved from CNKI, Wanfang, VIP, SinoMed, PubMed, EMbase, Cochrane Library, and Web of Science from inception to July 5, 2024. The distribution characteristics of evidence were presented numerically and graphically. A total of 35 Chinese patent medicines were identified, involving 261 articles. The basic information of the 35 Chinese patent medicines, publication trend, traditional Chinese medicine(TCM) syndromes, interventions, and outcome indicators were compared and analyzed, and the methodological quality of the articles was evaluated. The results indicated that the clinical scope of Chinese patent medicines in the treatment of ICH was broad. However, the available studies inadequately emphasized the advantages and characteristics of TCM, lacked the safety information and the standards for evaluating outcome indicators, and paid insufficient attention to cognitive ability and neuropsychology. In addition, these articles demonstrated low quality. It is recommended that follow-up clinical research should be standardized and highlight the characteristics of TCM. In the analysis of outcome indicators, TCM syndrome evaluation should be taken as an important outcome indicator, and the evaluation criteria should be unified. Moreover, more attention should be paid to patients' cognitive ability and neuropsychology. The holder of marketing license of Chinese patent medicines should standardize the clinical position and improve the safety information in the medicine instructions according to the relevant requirements of the National Medical Products Administration. Additionally, the proportion of Chinese patent medicines in the category A list of medical insurance should be increased, and the limited medical resources should be rationally allocated.
